<?xml version='1.0' encoding='utf-8'?>
<document id="21553654"><sentence text="Reversible inhibition of four important human liver cytochrome P450 enzymes by diethylstilbestrol."><entity charOffset="79-97" id="DDI-PubMed.21553654.s1.e0" text="diethylstilbestrol" /></sentence><sentence text="Diethylstilbestrol (DES), a synthetic estrogen clinically used to treat threatened abortion between the 1940s and the 1970s, has been restricted to treat certain cases of prostatic and breast cancer due to its adverse drug responses such as teratogenicity and carcinogenicity"><entity charOffset="0-18" id="DDI-PubMed.21553654.s2.e0" text="Diethylstilbestrol" /><entity charOffset="20-23" id="DDI-PubMed.21553654.s2.e1" text="DES" /><entity charOffset="38-46" id="DDI-PubMed.21553654.s2.e2" text="estrogen" /><pair ddi="true" e1="DDI-PubMed.21553654.s2.e0" e2="DDI-PubMed.21553654.s2.e0" /><pair ddi="true" e1="DDI-PubMed.21553654.s2.e0" e2="DDI-PubMed.21553654.s2.e1" /><pair ddi="true" e1="DDI-PubMed.21553654.s2.e0" e2="DDI-PubMed.21553654.s2.e2" /><pair ddi="false" e1="DDI-PubMed.21553654.s2.e1" e2="DDI-PubMed.21553654.s2.e1" /><pair ddi="false" e1="DDI-PubMed.21553654.s2.e1" e2="DDI-PubMed.21553654.s2.e2" /></sentence><sentence text=" Some reports have demonstrated that the addition of DES to docetaxel could modify tubulin composition and improve response of prostate cancer to chemotherapy"><entity charOffset="60-69" id="DDI-PubMed.21553654.s3.e0" text="docetaxel" /><entity charOffset="53-61" id="DDI-PubMed.21553654.s3.e1" text="DES" /><pair ddi="false" e1="DDI-PubMed.21553654.s3.e1" e2="DDI-PubMed.21553654.s3.e1" /><pair ddi="false" e1="DDI-PubMed.21553654.s3.e1" e2="DDI-PubMed.21553654.s3.e0" /></sentence><sentence text=" Given that DES might be co-administered with other drugs such as docetaxel, the present study focused on CYP-based drug-drug interaction (DDI)"><entity charOffset="66-75" id="DDI-PubMed.21553654.s4.e0" text="docetaxel" /><entity charOffset="12-20" id="DDI-PubMed.21553654.s4.e1" text="DES" /><pair ddi="false" e1="DDI-PubMed.21553654.s4.e1" e2="DDI-PubMed.21553654.s4.e1" /><pair ddi="false" e1="DDI-PubMed.21553654.s4.e1" e2="DDI-PubMed.21553654.s4.e0" /></sentence><sentence text=" In vitro inhibitory effects of DES on CYP isoforms were investigated, and the results showed that DES could competitively inhibit CYP3A4, CYP2C8, CYP2C9 and CYP2E1"><entity charOffset="32-34" id="DDI-PubMed.21553654.s5.e0" text="DES" /><entity charOffset="99-101" id="DDI-PubMed.21553654.s5.e1" text="DES" /><pair ddi="false" e1="DDI-PubMed.21553654.s5.e0" e2="DDI-PubMed.21553654.s5.e0" /><pair ddi="false" e1="DDI-PubMed.21553654.s5.e0" e2="DDI-PubMed.21553654.s5.e1" /></sentence><sentence text=" The inhibition constants (Ki) were calculated to be 4" /><sentence text="4 microM, 3" /><sentence text="0 microM, 5" /><sentence text="0 microM and 8" /><sentence text="0 microM for CYP3A4, CYP2C9, CYP2E1 and CYP2C8, respectively" /><sentence text=" Based on peak serum DES level after drip influsion of 500 mg of fosfestrol (DES diphosphate) in patients, [I]/Ki was calculated to be 4"><entity charOffset="65-75" id="DDI-PubMed.21553654.s11.e0" text="fosfestrol" /><entity charOffset="77-92" id="DDI-PubMed.21553654.s11.e1" text="DES diphosphate" /><entity charOffset="21-35" id="DDI-PubMed.21553654.s11.e2" text="DES" /><pair ddi="false" e1="DDI-PubMed.21553654.s11.e2" e2="DDI-PubMed.21553654.s11.e2" /><pair ddi="false" e1="DDI-PubMed.21553654.s11.e2" e2="DDI-PubMed.21553654.s11.e0" /><pair ddi="false" e1="DDI-PubMed.21553654.s11.e2" e2="DDI-PubMed.21553654.s11.e1" /><pair ddi="false" e1="DDI-PubMed.21553654.s11.e0" e2="DDI-PubMed.21553654.s11.e0" /><pair ddi="false" e1="DDI-PubMed.21553654.s11.e0" e2="DDI-PubMed.21553654.s11.e1" /></sentence><sentence text="3, 6" /><sentence text="2, 3" /><sentence text="7 and 2" /><sentence text="3 for CYP3A4, CYP2C9, CYP2E1 and CYP2C8, which suggested that DES was likely to induce in vivo DDI through inhibition of these four major CYP isoforms"><entity charOffset="62-64" id="DDI-PubMed.21553654.s15.e0" text="DES" /></sentence><sentence text=" These results collectively demonstrate that adverse drug responses might exist when DES is co-administered with other drugs"><entity charOffset="85-87" id="DDI-PubMed.21553654.s16.e0" text="DES" /></sentence><sentence text="" /></document>